• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 2
  • Tagged with
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Tweak and cIAP1 Mediate Alternative NF-κB Signalling to Promote Myogenesis

Adam, Nadine Jessica January 2016 (has links)
The NF-κB family of transcription factors can be activated through canonical (classical) or non-canonical (alternative) signalling pathways, which are regulated by the redundant ubiquitin ligases, cellular inhibitor of apoptosis 1 and 2 (cIAP1 and cIAP2). While the canonical NF-κB pathway is needed for myoblast proliferation, it is inactivated during myoblast differentiation. However, the non-canonical NF-κB pathway is a major factor in promoting myoblast fusion, which is crucial to the processes of myogenesis and muscle repair. Ablation of cIAP1 levels through a chemical antagonist such as a SMAC- mimetic compound (SMC) activates non-canonical signalling to enhance myogenesis. The cytokine TNF-like weak inducer of apoptosis (TWEAK) has also been shown to activate primarily the alternative NF-κB pathway when signalling through its receptor Fn14. Here I show that alternative NF-κB signalling activity, stimulated by the addition of TWEAK or loss of cIAP1, can promote myogenesis. I also demonstrate that TWEAK is an endogenous myokine produced by myoblasts to promote their own differentiation, and suggest that targeting the alternative NF-κB pathway, with SMAC-mimetics or recombinant TWEAK for example, would be of therapeutic value in the repair and regeneration of muscle for various myopathies.
2

Targeted quantitative proteomics in the NF-κB signalling pathway and the ubiquitin-proteasome system

Beaudette, Patrick Edmund 05 November 2018 (has links)
Die Aktivierung des NF-kB Vorläuferproteins p100 und p105 erfolgt durch eine proteasomale Trunkierung, um die aktiven p52 und p50 zu erzeugen. Zur Erforschung wurde eine Massenspektrometrie-basierende Proteomik-Strategie entwickelt, die mit der gezielten Reaktionsüberwachungstechnik plus einer Isotopenmarkierung verwendet wurde. In einem endogenen murinen embryonalen Fibroblasten-System konnte gezeigt werden, dass beide Vorläufer zu den jeweiligen Produkten in einer parallelen und sich einander bedingenden Weise in Reaktion auf einen Lymphotoxin-β-Rezeptor-Agonisten verarbeitet werden. Unsere SRM-SILAC- Methode erlaubte die Unterscheidung von Prä-Stimulationsprotein-Populationen aus Proteinen, die de novo nach der Stimulation synthetisiert wurden, und zeigte eine Tendenz für ältere Vorläufermoleküle, sich einer Degradation zu unterziehen, während die de novo-Moleküle auf die Produkte verarbeitet wurden. Die langsame und anhaltende Kinetik, die ein typisches Merkmal des nicht-kanonischen NF-κB- Weges ist. Darüber hinaus, konnten wir beobachten, dass die hydrolytische Aktivität der AAA ATPase VCP / p97 in der Bildung von de novo p52 und p50 eine Rolle spielt. Durch ein MS-basiertes Screening für strahlungsinduzierte Protein-Interaktoren eines weiteren NF-κB-Players, der die regulatorische Untereinheit des IKK-Komplexes IKKγ / NEMO bildet, konnte der Enhancer von mRNA Decapping 4 (EDC4) entdeckt werden. Durch die zusätzliche Untersuchung der E3-Ligase, Parkin, konnte eine Verbindung mit dem NF-κB-Weg durch eine lineare Ubiquitinierung hergestellt werden. Es konnte gezeigt werden, dass Parkin ist Hauptkomponenten des linearen Ubiquitin-Ketten-Assemblierungskomplexes (LUBAC). Die Proteomanalyse im Proteinkinase A (PKA) -Signalisierungsweg konnte zwei neuartige Regulationsformen identifizieren: K63-verknüpfte Polyubiquitinierung die katalytische Untereinheit von PKA, PKAC in Richtung eines lysosomalen pathways führt, und auch durch einen Pseudosubstrat-Hemmungsmechanismus. / Activation of the NF-κB precursor protein p100 and p105 by a specific proteasomal truncation to yield the active products p52 and p50 is a distinct feature of the non- canonical pathway but the mechanism governing it remains elusive. A novel mass spectrometry-based proteomics strategy was developed, using the targeted selected reaction monitoring technique in conjunction with stable isotope labeling for both absolute quantitation of proteins and to mark precursor protein populations relative to the application of the lymphotoxin β stimulation. In an endogenous murine embryonic fibroblast system, we have shown that both precursors are processed to the respective products in a parallel and interdependent manner in response to a lymphotoxin β receptor agonist. Our Dynamic SRM-SILAC method allowed distinction of pre-stimulation protein populations from proteins synthesized de novo post- stimulation, and revealed a tendency for older precursor molecules to undergo degradation while the de novo molecules went on to be processed to the products, accounting for the slow and persistent kinetics that are a hallmark of the non- canonical NF-κB pathway. In addition, the hydrolytic activity of the AAA ATPase VCP/p97 was implicated in the generation of de novo p52 and p50. An MS-based proteomics screen for specific, radiation-induced protein interactors of another key NF-κB player, the regulatory subunit of the IKK complex, IKKγ/NEMO, turned up the Enhancer of mRNA Decapping 4 (EDC4). This unexpected finding has expanded the known role of NF-κB regulation of protein levels beyond transcription into mRNA stability. Separate investigations into the ubiquitin E3 ligase, parkin, connected it to the NF-κB pathway through a linear ubiquitination it helps catalyze on IKKγ/NEMO. Proteomic analysis of polyubiquitin in the protein kinase A (PKA) signalling pathway helped to identify two novel modes of regulation: a lysosomal degradation pathway; as well as a pseudosubstrate inhibition mechanism.

Page generated in 0.0847 seconds